Merck & Co Inc (MRK)

MRK on New York Consolidated

59.66USD
21 Nov 2014
Price Change (% chg)

$0.28 (+0.47%)
Prev Close
$59.38
Open
$59.94
Day's High
$60.02
Day's Low
$59.33
Volume
11,260,375
Avg. Vol
10,525,974
52-wk High
$61.33
52-wk Low
$47.61

MRK

Chart for MRK

About

Merck & Co., Inc. (Merck), is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company consists of four operating segments, which are the Pharmaceut... (more)

Overall

Beta: 0.33
Market Cap (Mil.): $169,284.91
Shares Outstanding (Mil.): 2,850.87
Dividend: 0.44
Yield (%): 2.96

Financials

  MRK Industry Sector
P/E (TTM): 32.55 38.05 39.20
EPS (TTM): 1.82 -- --
ROI: 6.72 17.86 17.16
ROE: 11.63 18.61 18.09
Search Stocks

Britain begins review to speed access to new drugs

* Innovative Medicines and MedTech Review to report in 2015

20 Nov 2014

Merck's Zetia cuts heart attack, stroke risk in long-awaited study

CHICAGO - After years of uncertainty, a nearly decade-long study showed that Merck & Co's cholesterol drug Zetia lowered the risk of heart attacks and strokes in high-risk heart patients when used with an effective statin.

17 Nov 2014

UPDATE 1-Merck's Zetia cuts heart attack, stroke risk in long-awaited study

CHICAGO, Nov 17 - After years of uncertainty, a nearly decade-long study showed that Merck & Co's cholesterol drug Zetia lowered the risk of heart attacks and strokes in high-risk heart patients when used with an effective statin.

17 Nov 2014

ECB's Draghi helps European shares reverse early losses

* Weir hit by renewed slump in crude (Updates with closing prices)

17 Nov 2014

Regeneron drug highly effective for those who can't take statins: study

CHICAGO - Regeneron Corp's experimental drug alirocumab helped 10 times as many high-risk patients unable to tolerate widely-used statins get their "bad" LDL cholesterol down to target levels than Merck & Co's Zetia, according to data from a clinical trial presented on Monday.

17 Nov 2014

Regeneron drug highly effective for those who can't take statins -study

CHICAGO, Nov 17 - Regeneron Corp's experimental drug alirocumab helped 10 times as many high-risk patients unable to tolerate widely-used statins get their "bad" LDL cholesterol down to target levels than Merck & Co's Zetia, according to data from a clinical trial presented on Monday.

17 Nov 2014

ECB's Draghi helps European shares reverse early losses

* Weir hit by renewed slump in crude (Recasts, adds quotes, detail)

17 Nov 2014

Merck's Zetia cuts heart attack, stroke risk in long-awaited study

CHICAGO, Nov 17 - After years of uncertainty, a nearly decade-long study showed that Merck & Co's cholesterol drug Zetia significantly lowered the risk of heart attacks and strokes in high-risk heart patients when used with a highly effective statin.

17 Nov 2014

European shares pare losses after Japan slips into recession

* Weir hit by renewed slump in crude (Adds detail, quotes, updates prices)

17 Nov 2014

U.S. gene study raises hope for Merck cholesterol drug Zetia

CHICAGO - Rare mutations in a single gene may help lower cholesterol and reduce the risk of a heart attack by half, U.S. researchers said on Wednesday in a study that could have implications for Merck and Co's closely watched heart drug Zetia.

12 Nov 2014

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Wright Reports
$75.00
Provider: Stock Traders Daily
$20.00
Provider: S&P Capital IQ – STARS Reports
$127.00
Provider: Stock Traders Daily
$20.00
Provider: Pechala's Reports
$15.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks